HLN logo

Haleon plcNYSE:HLN 株式レポート

時価総額 US$42.9b
株価
n/a
1Y-0.4%
7D0.7%
1D1.5%
ポートフォリオ価値
​
表示

Haleon plc

NYSE:HLN 株式レポート

時価総額：US$42.9b

Haleon（HLN）株式概要

ハレオン社は、その子会社とともに、北米、欧州、中東、アフリカ、中南米、アジア太平洋地域で、さまざまな消費者向けヘルスケア製品の研究、開発、製造、販売に従事している。 詳細

HLN ファンダメンタル分析
スノーフレーク・スコア
評価4/6
将来の成長1/6
過去の実績5/6
財務の健全性2/6
配当金3/6

報酬

当社が推定した公正価値より44.3%で取引されている

収益は年間8.15%増加すると予測されています

過去1年間で収益は6.6%増加しました

リスク分析

多額の負債を抱えている


HLN Community Fair Values

Create Narrative

See what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW461,592 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
461,592 investors already sharing narratives
View all narratives

Haleon plc 競合他社

価格と性能

株価の高値、安値、推移の概要Haleon
過去の株価
現在の株価UK£9.87
52週高値UK£11.28
52週安値UK£8.65
ベータ0.25
1ヶ月の変化-1.69%
3ヶ月変化5.90%
1年変化-0.40%
3年間の変化18.06%
5年間の変化n/a
IPOからの変化31.60%

最新ニュース

Seeking Alpha • Jun 15

Haleon: Waiting For A Good Entry Point In Consumer Healthcare Leader

Summary Haleon delivered a 15.6% net profit increase in 2025, driven by cost controls and margin expansion despite modest revenue decline. HLN generated £1.5B in net free cash flow, supporting £650M in share buybacks and £612M in dividends, while reducing leverage to 2.6x EBITDA. Management guided for 3–5% organic revenue growth in 2026, with Q1 organic growth at 2.2% and expectations for acceleration through the year. Valuation at 12–13x EV/EBITDA is justified by HLN’s consumer healthcare dominance. Consensus sees EBITDA multiples declining to 10–10.5x by 2028. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Jun 15

Haleon: Waiting For A Good Entry Point In Consumer Healthcare Leader

Summary Haleon delivered a 15.6% net profit increase in 2025, driven by cost controls and margin expansion despite modest revenue decline. HLN generated £1.5B in net free cash flow, supporting £650M in share buybacks and £612M in dividends, while reducing leverage to 2.6x EBITDA. Management guided for 3–5% organic revenue growth in 2026, with Q1 organic growth at 2.2% and expectations for acceleration through the year. Valuation at 12–13x EV/EBITDA is justified by HLN’s consumer healthcare dominance. Consensus sees EBITDA multiples declining to 10–10.5x by 2028. Read the full article on Seeking Alpha
Seeking Alpha • Mar 05

Haleon: Growing Profits And Dividend

Summary I initiate coverage on Haleon with a "hold" rating due to decent results and potential for ongoing growth, despite a slight revenue slip last year. Haleon's dividend grew 10% and is well-covered by free cash flow, but the 1.6% yield is less attractive compared to peers. The balance sheet is manageable with net debt at 22% of market cap, though I question the optimality of share buybacks at current prices. The current valuation, with a P/E ratio of 26, isn't compelling for new investment, though ongoing earnings growth suggests no reason for existing shareholders to sell. Read the full article on Seeking Alpha
Seeking Alpha • Dec 10

Haleon: Guidance Implies Uncertainty Around Flu Season

Summary Haleon plc is logging solid organic performances led by their solid brand portfolio for oral health with brands like Sensodyne and Parodontax. This is despite some tough comps still in the results, particularly in VMS. Guidance remains around the 4-6% organic growth figure, ignoring FX effects, despite the momentum in the Q3. This reflects that there is still uncertainty of how much of a plus this year's flu season will be for respiratory products, despite the weak comp. The biggest observation we make though is that the HLN stock valuation is just not attractive enough. Read the full article on Seeking Alpha
Seeking Alpha • Oct 24

Haleon: Tailwinds Are Mostly Priced In

Summary Haleon's share price increased by 20% since July, mainly driven by strong H1 2024 results and strategic moves, among them, increasing their stake in Tianjin TSKF Pharmaceutical. The upcoming launch of Eroxon and China's stimulus pack could improve future sales, but debt maturity in 2025 may hinder deleveraging plans. Institutional investor activity shows growing optimism in Q2 2024, but recent major fund buying is absent, contributing to the mixed outlook. Despite strong cash flow and organic growth in most of its key brands, high leverage and mixed valuation ratios lead to a Hold rating for Haleon. Read the full article on Seeking Alpha
Seeking Alpha • Aug 06

Haleon: Defensive Consumer Healthcare Stock As Safe Haven

Summary Haleon is a consumer healthcare company formed from a GSK and Pfizer merger, with a 50% share price increase since trading began. Financial results show strong cash flows, with a net profit of 754M GBP and EPS of 7.90 pence per share in the first half of the year. Investment thesis suggests writing put options due to the high EBITDA multiple, with the potential for decreasing net debt and increasing EBITDA in the future. Read the full article on Seeking Alpha
Seeking Alpha • Nov 20

The Investment Case For Haleon: Steady Shareholder Value Accumulation

Summary Haleon plc is a promising company in the personal care products sector, with a low beta and cheap valuation. The company operates globally and has leading brands in oral health, painkillers, and vitamins. Haleon's ownership structure is interconnected with Pfizer and GSK, but divestitures could increase competitive pressures. My valuation analysis suggests the stock is significantly undervalued, implying a 44.6% upside potential and an $11.92 price target. Read the full article on Seeking Alpha
Seeking Alpha • Sep 07

The Share Price Has The Flu, But Haleon Is As Healthy As An Ox

Summary Haleon's share price has slumped, but its performance is relatively better compared to its consumer staples peers and the recent listing Kenvue. HLN has delivered solid results with organic revenue growth, increased operating profits, and raised revenue forecasts for FY2023. The company is optimizing its portfolio, divesting the Lamisil brand, reducing debt, and generating strong cash flow. Power brands are driving performance. Read the full article on Seeking Alpha
Seeking Alpha • Jun 12

Haleon: A Hidden Gem In The Consumer Health Market

Summary Haleon has a strong portfolio of leading brands and is well-positioned to benefit from ongoing market expansions. The company's latest earnings were strong, with double-digit growth in both the top and the bottom line. Despite the solid fundamentals and growth, its current valuation remains discounted compared to peers. I rate the company as a buy. Read the full article on Seeking Alpha
Seeking Alpha • Feb 25

Haleon exploring sale of ChapStick Brand - report

Haleon Plc (NYSE:HLN), the consumer health unit spun off from GSK Plc last year, is evaluating a sale of its ChapStick lip balm brand. The company is working with advisers and the business could see $600 million in a potential sale, according to a Bloomberg report from Friday, which cited people familiar. Deliberations on a possible sale are said to be at an early stage. The news comes after Bloomberg late last month reported that Haleon (HLN) was in the early stages of evaluating large potential deals to increase the size of its brand portfolio. Haleon was said to be studying possible deals in the medium-to-long-term, including potentially combining with Sanofi's (SNY) $30 billion consumer-health business. Haleon (HLN) is set to report Q4 results on Thursday. Also see SA contributor Yannick Frey's piece from last month entitled "Haleon: A Great Consumer Staples Add."
Seeking Alpha • Jan 31

Haleon said to evaluate potential deals to increase its size - report

Haleon Plc (NYSE:HLN), the consumer health business spun of from pharmaceutical giant GSK Plc (GSK), is in the early stages of evaluating large potential deal to increase the size of its brand portfolio. Haleon (HLN) is studying possible deals in medium-to-long-term, including potentially combining with Sanofi's (NASDAQ:SNY) $30 billion consumer-health business, according to traders, who cited a Bloomberg report. The maker of Advil pain reliever and Aquafresh toothpaste is expected to wait until it can show several quarters of profit grown and debt paydown before it goes forward with any big transactions, according to the report. The report comes as Johnson & Johnson (JNJ) is preparing to list its consumer health business this year, though analysts cautioned on Monday that the legal judgement against J&J in talc litigation may complicate that process. Bayer (OTCPK:BAYRY) is also seeing pressure from activists investors, including one who earlier this month pushed for the German company to separate its crop sciences business from its consumer drug business.
Seeking Alpha • Aug 31

Haleon: Undervalued With Clear Catalyst Ahead

Summary Haleon has tumbled 20% since trading began in July. The stock is undervalued relative to its peers. The announcement of a dividend should boost the stock to higher levels. Earlier this year, GSK plc (GSK) decided to focus its business on vaccines and prescription medication. As a result, the company spun-off its consumer health business. The newly created company, Haleon plc (HLN), is now the largest standalone consumer health business. It owns many household brands, including Advil, Emergen-C, Tums and Sensodyne. The company is a powerhouse in the consumer staples industry, with around $11.5 billion in annual sales. The stock began trading on July 18, 2022, and has been steadily trading lower, down 20% since trading started. This article will focus on the stock's value versus peers as well as a significant catalyst that could lead to the stock finding a floor and climbing higher. Haleon Fact Sheet Haleon is Undervalued Yahoo Finance and CNBC Anyway, you analyze Haleon, it is undervalued versus its peers in the industry. Comparing Haleon to three of the biggest companies in consumer staples - Procter & Gamble (PG), Unilever (UL, UNLYF), and Kimberly-Clark (KMB) - the company stacks up well on a number of valuation metrics. Its P/E value of 14.6 is 56% below the average P/E ratio of the 3 peers. This also puts the stock at a discount to the broader S&P 500 as well. Whenever you see a stock trading at a steep discount to its peers, investors should then look at the company's margin and growth level to see if the undervaluation is warranted. Here, you can again see Haleon stacking up very well. The company has an attractive net margin of 15.7%, which is well above Unilever and Kimberly-Clark. Perhaps, more importantly, the company expects its margins to hold up even in today's challenging market environment. Haleon saw a very strong second quarter revenue growth of 12.9% and organic revenue growth of 7.5%. The organic revenue growth came from a 4% increase in price and improved volumes of 3.5%. This combination shows consumers are willing to pay higher prices to continue to buy Haleon's product lineup in a very competitive market. For the full year FY2022, the company expects organic growth of 6-8% and 4-6% over the following 2 years. This steady growth is exactly what investors want to see and is attractive versus its peers over a 5-year period. PG Revenue (Annual YoY Growth) data by YCharts Haleon Underperformance With Haleon having attractive revenue growth, healthy margins and trading at a discount relative to its peers, why has the stock performed so poorly since its debut? Both the company and the stock are in a transition period. When Haleon was spun-off from GSK, all GSK shareholders received 1 Haleon share for every GSK share they held. 54.5% of Haleon stock was held by GSK shareholders at the time of the spin-off. These investors held GSK for exposure to pharma and not necessarily consumer healthcare. As a result, many of the current GSK shareholders likely sold during the first few weeks as it didn't meet their portfolio needs or sold to raise cash in a very uncertain market. In addition, shortly after it began trading as a standalone company, news of a growing lawsuit emerged that targeted a probable carcinogen in the popular heartburn drug, Zantac. Zantac was originally formulated and sold by GSK in the 1980s. GSK's patent expired in 1997, and since then numerous pharmaceutical companies have owned the rights to Zantac, including Pfizer (PFE), Sanofi (SNY) and Boehringer Ingelheim. With the first legal proceedings of this lawsuit starting in late August, investors began to fear an outcome similar to that faced by Bayer when they agreed to a $10.9 billion settlement related to lawsuits targeting a link between Roundup and cancer. However, the lawsuit targeting Zantac is extremely complex due to the drug being sold for nearly 4 decades by numerous different pharma companies. These lawsuits will be locked up in the courts for years to come and has a long way to go before any outcome is even clear. Haleon shares fell over 10% as news of the start of the trial emerged. Haleon issued a statement about the lawsuit where they stated Haleon is not a party to any of the Zantac claims and the company never marketed Zantac in any form in the U.S. Haleon may end up having some exposure to the lawsuit, but it will likely be limited due to the number of other companies involved, and no clear result will be known for years. As a result, the issue should remain on investors' radar, but shouldn't be front of mind or alter investment decisions. Haleon Catalyst As I said above, Haleon's stock is in a transition period and in a bit of a no-man's land. It's a newly created consumer healthcare company with plenty of comps, but the biggest difference between it and its peers is the dividend. Currently, Haleon pays no dividend. As a result, it doesn't meet many investor needs or criteria. Mutual funds, pensions, endowments and retail investors are large holders of Procter & Gamble, Unilever and Kimberly-Clark because they are steady businesses during favorable and unfavorable economic conditions that pay a steady dividend. Currently, Haleon doesn't offer this steady income that many investors rely on in their portfolios. However, the company has stated they intend to start paying a dividend at the lower end of a 30-50% payout ratio. Assuming the company starts its payout ratio at 30% and EPS of 0.42, the initial dividend will likely be around $0.12-$0.13/share. This would give the stock an initial dividend yield around 2% based on its current price around $6/share. This would also give the company plenty of room to accomplish their other objective to get their net debt/EBITDA under 3 by the end of 2024.
Seeking Alpha • Aug 19

Former GSK consumer health unit Haleon hits all-time low

Haleon (NYSE:HLN), which only began trading on the NYSE on July 19, has fallen to an all-time low. The GlaxoSmithKline (GSK) consumer healthcare spinoff opened that date at $7.25. Earlier Friday, it reached a low of $5.95. Haleon (HLN) and GSK (GSK) have both been negatively impacted recently by potential exposure to litigation related to the recalled heartburn drug Zantac (ranitidine).
Seeking Alpha • Jul 20

Haleon CEO says brand recognition, gross margins will drive growth - CNBC

On its third day as a company separate from GlaxoSmithKline (GSK), Haleon (HLN) CEO Brian McNamara said that the customer recognition of its many brands combined with hits high gross margin rate will power growth in the future, he said. In an interview on CNBC's "Squawk Box" Wednesday morning, McNamara said that the former GSK (GSK) consumer healthcare unit had a gross margin of 63% and an operating margin of 22.8% in 2021. "With that gross margin and strength in brands, [it] really gives us the ability to invest in innovation and advertising and promotion to really drive the fundamental growth of the business," he added. Despite a plethora of store and generic-branded consumer healthcare products, McNamara noted that "brands really matter in the health space." Haleon (HLN) management has previously guided to 4%-6% net sales growth annually. Haleon (HLN) began trading on the London Stock Exchange on Monday. Since then, shares are down ~8%. The company made its trading debut on the NYSE today. In late morning trading, shares are up 0.4%.

株主還元

HLNUS PharmaceuticalsUS 市場
7D0.7%6.0%-0.8%
1Y-0.4%59.4%20.5%

業界別リターン: HLN過去 1 年間で59.4 % の収益を上げたUS Pharmaceuticals業界を下回りました。

リターン対市場: HLNは、過去 1 年間で20.5 % のリターンを上げたUS市場を下回りました。

価格変動

Is HLN's price volatile compared to industry and market?
HLN volatility
HLN Average Weekly Movement3.5%
Pharmaceuticals Industry Average Movement9.2%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

安定した株価: HLN 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。

時間の経過による変動: HLNの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。

会社概要

設立従業員CEO（最高経営責任者ウェブサイト
171524,535Brian McNamarawww.haleon.com

Haleon plcは、子会社とともに、北米、欧州、中東、アフリカ、ラテンアメリカ、およびアジア太平洋地域において、さまざまなコンシューマーヘルスケア製品の研究、開発、製造、販売を行っています。 同社は、「Sensodyne」、「Polident」、「Parodontax」、「Biotene」の各ブランドで、歯磨き粉、マウスウォッシュ、入れ歯用ケア製品などの口腔衛生製品を提供しているほか、「Centrum」、「Emergen-C」、「Caltrate」の各ブランドで、ビタミン、ミネラル、サプリメントを提供している。 また、呼吸器系の問題に対しては、「Theraflu」および「Flonase」ブランドによる点鼻薬、風邪・インフルエンザ・アレルギー緩和製品、消化器系の健康やその他の問題に対しては、「Voltaren」、「Panadol」、「Advil」ブランドによる鎮痛製品、「TUMS」、「ENO」、 フェニスティルなどのブランド名で、制酸剤や抗ヒスタミン剤などを提供しています。Haleon plcは、マイクロソフトと提携契約を締結し、事業全体でデジタル、データ、AIの能力を拡大するとともに、「One Win as One」戦略のグローバルな展開を加速させています。 Haleon plcは、以前はDRVW 2022 plcとして知られていましたが、2022年2月にHaleon plcに社名を変更しました。同社は1715年に設立され、英国ウェイブリッジに本社を置いています。

Haleon plc 基礎のまとめ

Haleon の収益と売上を時価総額と比較するとどうか。
HLN 基礎統計学
時価総額US$42.90b
収益（TTM）US$2.21b
売上高(TTM)US$15.18b
19.4x
PER（株価収益率
2.8x
P/Sレシオ

HLN は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
HLN 損益計算書（TTM）
収益UK£11.15b
売上原価UK£3.84b
売上総利益UK£7.31b
その他の費用UK£5.69b
収益UK£1.62b

直近の収益報告

Jun 30, 2026

次回決算日

該当なし

一株当たり利益（EPS）0.18
グロス・マージン65.57%
純利益率14.55%
有利子負債／自己資本比率49.2%

HLN の長期的なパフォーマンスは？

過去の実績と比較を見る

配当金

2.0%
現在の配当利回り
40%
配当性向

HLN 配当は確実ですか？

HLN 配当履歴とベンチマークを見る
HLN 、いつまでに購入すれば配当金を受け取れますか？
Haleon 配当日
配当落ち日Aug 14 2026
配当支払日Sep 17 2026
配当落ちまでの日数7 days
配当支払日までの日数27 days

HLN 配当は確実ですか？

HLN 配当履歴とベンチマークを見る

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/08/19 18:58
終値2026/08/19 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Haleon plc 16 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。26

アナリスト機関
Iain SimpsonBarclays
Warren AckermanBarclays
Bethan DaviesBerenberg